| Title | Ablation therapy using a low dose of radioiodine may be sufficient in low- to intermediate-risk patients with follicular variant papillary thyroid carcinoma. |
| Publication Type | Journal Article |
| Year of Publication | 2020 |
| Authors | Li F, Li W, Gray KD, Zarnegar R, Wang D, Fahey TJ |
| Journal | J Int Med Res |
| Volume | 48 |
| Issue | 11 |
| Pagination | 300060520966491 |
| Date Published | 2020 Nov |
| ISSN | 1473-2300 |
| Abstract | OBJECTIVES: Follicular variant papillary thyroid carcinoma (FVPTC) is treated similarly to classical variant papillary thyroid carcinoma (cPTC). However, FVPTC has unique tumour features and behaviours. We investigated whether a low dose of radioiodine was as effective as a high dose for remnant ablation in patients with FVPTC and evaluated the recurrence of low-intermediate risk FVPTC. METHODS: Data from cPTC and FVPTC patients treated with I-131 from 2004 to 2014 were reviewed. Demographics, tumour behaviour, lymph node metastasis, and local recurrence data were compared between FVPTC and cPTC patients. Then, low-intermediate risk FVPTC patients were divided into low, intermediate, and high I-131 dose groups, and postoperative I-131 activities were analysed to evaluate the effectiveness of I-131 therapy for thyroid remnant ablation. RESULTS: In total, 799 cases of FVPTC (nā=ā168) and cPTC (nā=ā631) treated with I-131 were identified. Patients with FVPTC had a larger primary nodule size than cPTC, but lymph node metastases and local recurrence were more prevalent in cPTC than in FVPTC. For the low-, intermediate-, and high-dose groups, success rates of ablation did not differ (82.0%, 80%, and 81.3%, respectively). CONCLUSION: FVPTC differs from cPTC in behaviour. Low-dose ablation may be sufficient in FVPTC patients with low-intermediate disease risk. |
| DOI | 10.1177/0300060520966491 |
| Alternate Journal | J Int Med Res |
| PubMed ID | 33213252 |
| PubMed Central ID | PMC7683922 |
